Oral remibrutinib hits Phase 3 primary endpoint for inducible hives
1. Oral remibrutinib successfully met its primary endpoint in the Phase III RemIND trial, delivering significant symptom relief for chronic ...
1. Oral remibrutinib successfully met its primary endpoint in the Phase III RemIND trial, delivering significant symptom relief for chronic ...
Lilly unveils TuneLab AI platform for biotechs On September 9, 2025, Eli Lilly officially unveiled TuneLab, a federated AI platform ...
1. Artificial intelligence triage for melanoma shows more than 90 percent sensitivity and is now in trials within the National ...
Google’s AI matches dermatologists in melanoma diagnosis England’s health service is piloting an artificial intelligence tool called Deep Ensemble for ...
1. Among patients with melasma, microneedling with tranexamic acid was superior to microneedling with metformin or the control treatment in ...
1. In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on second-generation ...
1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant ...
1. The use of rituximab, abatacept and Janus kinase inhibitors (JAKis) in individuals with rheumatoid arthritis (RA) was associated with ...
1. After almost 10 years of follow-up, adjuvant dabrafenib and trametinib improved relapse-free and metastasis-free survival compared to placebo in ...
1. More patients in the delgocitinib cream group reported clear or almost clear skin at week 16 in both the ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.